Posts by Mourabit Halima

The annual meeting of the European Hematology Association (EHA) is an international conference in the field of hematology, bringing together numerous experts and scholars from around the world to share and delve into innovative ideas and research progress, promoting continuous development in the field of hematology. This year, the research achievements of spleen tyrosine kinase (SYK) inhibitors attracted significant attention. HMPL-523 (Solepinib), the first SYK inhibitor from China to apply for market approval (*as of the press date), presented multiple research results at the EHA conference. In this issue, "Oncology Frontier - Hematology Frontier" invited Dr. Jing Sun from the Department of Hematology at Nanfang Hospital, Southern Medical University, to provide an in-depth interpretation of the ESLIM-01 study (NCT05029635) on Solepinib in the treatment of primary immune thrombocytopenia (ITP), aiming to offer clinical practice insights.

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology. He shared his profound insights and unique academic perspectives on major studies presented at ASCO this year, the progress of the novel CD3 x CD19 IgG4 bispecific antibody CN201, and the overall status and future prospects of hematologic oncology treatment in China.

TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo Bertossi from the Department of Internal Medicine III at the University of Ulm in Germany, through an exciting oral presentation, deeply analyzed the "The Landscape of TP53 Mutations and Their Prognostic Impact in Chronic Lymphocytic Leukemia (S101)", providing valuable data and insights for the attendees, which has important guiding value for clinical practice and scientific research exploration. To further discuss this cutting-edge topic, "Oncology Frontier-Hematology Frontier" specially invited Dr. Consuelo Bertossi for an interview on the spot, sharing the impact of TP53 mutations on survival rates, the efficacy of targeted drugs, and future research directions.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Li Bao from Beijing Jishuitan Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier invited Dr. Kai Hu from Beijing GoBroad Hospital for an exclusive interview. He provided insightful explanations on the topic of "The Application of Immunotherapy in Lymphoma/Myeloma."

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. At this conference, Dr. Lin Fu from the Department of Hematology at Beijing Tiantan Hospital delivered an insightful presentation on the "Advances in Diagnosis and Treatment of Primary Central Nervous System Lymphoma (PCNSL)." To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier conducted an exclusive interview with Dr. Lin Fu. The following is a summary for readers' reference.